Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26


Assessing the reporting quality of influenza outbreaks in the community.

Lo C, Mertz D, Loeb M.

Influenza Other Respir Viruses. 2017 Nov;11(6):556-563. doi: 10.1111/irv.12516.


Drug resistance in influenza A virus: the epidemiology and management.

Hussain M, Galvin HD, Haw TY, Nutsford AN, Husain M.

Infect Drug Resist. 2017 Apr 20;10:121-134. doi: 10.2147/IDR.S105473. eCollection 2017. Review.


Molecular Mechanism Underlying the Action of Influenza A Virus Fusion Inhibitor MBX2546.

Basu A, Komazin-Meredith G, McCarthy C, Antanasijevic A, Cardinale SC, Mishra RK, Barnard DL, Caffrey M, Rong L, Bowlin TL.

ACS Infect Dis. 2017 May 12;3(5):330-335. doi: 10.1021/acsinfecdis.6b00194. Epub 2017 Apr 3.


A Narrative Review of Influenza: A Seasonal and Pandemic Disease.

Moghadami M.

Iran J Med Sci. 2017 Jan;42(1):2-13. Review.


Oseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection.

Boianelli A, Sharma-Chawla N, Bruder D, Hernandez-Vargas EA.

Front Cell Infect Microbiol. 2016 Jun 14;6:60. doi: 10.3389/fcimb.2016.00060. eCollection 2016.


How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation.

Waghmare A, Englund JA, Boeckh M.

Blood. 2016 Jun 2;127(22):2682-92. doi: 10.1182/blood-2016-01-634873. Epub 2016 Mar 11. Review.


Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.

Song MS, Marathe BM, Kumar G, Wong SS, Rubrum A, Zanin M, Choi YK, Webster RG, Govorkova EA, Webby RJ.

J Virol. 2015 Nov;89(21):10891-900. doi: 10.1128/JVI.01514-15. Epub 2015 Aug 19.


Generation of Adaptive Immune Responses Following Influenza Virus Challenge is Not Compromised by Pre-Treatment with the TLR-2 Agonist Pam2Cys.

Mifsud EJ, Tan AC, Brown LE, Chua BY, Jackson DC.

Front Immunol. 2015 Jun 5;6:290. doi: 10.3389/fimmu.2015.00290. eCollection 2015.


Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.

Baek YH, Song MS, Lee EY, Kim YI, Kim EH, Park SJ, Park KJ, Kwon HI, Pascua PN, Lim GJ, Kim S, Yoon SW, Kim MH, Webby RJ, Choi YK.

J Virol. 2015 Jan;89(1):287-99. doi: 10.1128/JVI.02485-14. Epub 2014 Oct 15.


Deep sequencing: becoming a critical tool in clinical virology.

QuiƱones-Mateu ME, Avila S, Reyes-Teran G, Martinez MA.

J Clin Virol. 2014 Sep;61(1):9-19. doi: 10.1016/j.jcv.2014.06.013. Epub 2014 Jun 24. Review.


A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last Decade.

Oh DY, Hurt AC.

Scientifica (Cairo). 2014;2014:430629. doi: 10.1155/2014/430629. Epub 2014 Apr 2. Review.


Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study.

Canini L, Conway JM, Perelson AS, Carrat F.

PLoS Comput Biol. 2014 Apr 17;10(4):e1003568. doi: 10.1371/journal.pcbi.1003568. eCollection 2014 Apr. Erratum in: PLoS Comput Biol. 2014 Jun;10(6):e1003699.


Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses.

Butler J, Hooper KA, Petrie S, Lee R, Maurer-Stroh S, Reh L, Guarnaccia T, Baas C, Xue L, Vitesnik S, Leang SK, McVernon J, Kelso A, Barr IG, McCaw JM, Bloom JD, Hurt AC.

PLoS Pathog. 2014 Apr 3;10(4):e1004065. doi: 10.1371/journal.ppat.1004065. eCollection 2014 Apr.


Antivirals in the 2009 pandemic--lessons and implications for future strategies.

Berera D, Zambon M.

Influenza Other Respir Viruses. 2013 Nov;7 Suppl 3:72-9. doi: 10.1111/irv.12172. Review.


New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion.

Basu A, Antanasijevic A, Wang M, Li B, Mills DM, Ames JA, Nash PJ, Williams JD, Peet NP, Moir DT, Prichard MN, Keith KA, Barnard DL, Caffrey M, Rong L, Bowlin TL.

J Virol. 2014 Feb;88(3):1447-60. doi: 10.1128/JVI.01225-13. Epub 2013 Nov 6.


Nosocomial outbreak of the pandemic Influenza A (H1N1) 2009 in critical hematologic patients during seasonal influenza 2010-2011: detection of oseltamivir resistant variant viruses.

Pollara CP, Piccinelli G, Rossi G, Cattaneo C, Perandin F, Corbellini S, Tomasi DD, Bonfanti C.

BMC Infect Dis. 2013 Mar 7;13:127. doi: 10.1186/1471-2334-13-127.


Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

McKimm-Breschkin JL.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:25-36. doi: 10.1111/irv.12047. Review.


Exhaled air dispersion during coughing with and without wearing a surgical or N95 mask.

Hui DS, Chow BK, Chu L, Ng SS, Lee N, Gin T, Chan MT.

PLoS One. 2012;7(12):e50845. doi: 10.1371/journal.pone.0050845. Epub 2012 Dec 5.


Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation.

Wong DD, Choy KT, Chan RW, Sia SF, Chiu HP, Cheung PP, Chan MC, Peiris JS, Yen HL.

J Virol. 2012 Oct;86(19):10558-70. doi: 10.1128/JVI.00985-12. Epub 2012 Jul 18.


Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia.

Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Leang SK, Lee RT, Iannello P, Gehrig N, Shaw R, Wark P, Caldwell N, Givney RC, Xue L, Maurer-Stroh S, Dwyer DE, Wang B, Smith DW, Levy A, Booy R, Dixit R, Merritt T, Kelso A, Dalton C, Durrheim D, Barr IG.

J Infect Dis. 2012 Jul 15;206(2):148-57. doi: 10.1093/infdis/jis337. Epub 2012 May 4.

Supplemental Content

Support Center